Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy.

Enfermedades infecciosas y microbiología clínica
Raquel Parra-MillánY Smani

Abstract

Immune response stimulation may be an adjuvant to antimicrobial treatment. Here, we evaluated the impact of immune response modification by lysophosphatidylcholine (LPC), combined with imipenem or ceftazidime, in murine models of peritoneal sepsis (PS) and pneumonia induced by Pseudomonas aeruginosa. The imipenem and ceftazidime-susceptible strain (Pa39) and imipenem and ceftazidime-resistant strain (Pa238) were used. Ceftazidime pharmacokinetic and pharmacodynamic parameters were determined. The therapeutic efficacy and TNF-α and IL-10 levels were determined in murine models of PS and pneumonia induced by Pa39 and Pa238 and treated with LPC, imipenem or ceftazidime, alone or in combination. In the PS model, LPC+ceftazidime reduced spleen and lung Pa238 concentrations (-3.45 and -3.56log10CFU/g; P<0.05) to a greater extent than ceftazidime monotherapy, while LPC+imipenem maintained the imipenem efficacy (-1.66 and -1.45log10CFU/g; P>0.05). In the pneumonia model, LPC+ceftazidime or LPC+imipenem reduced the lung Pa238 concentrations (-2.37log10CFU/g, P=0.1, or -1.35log10CFU/g, P=0.75). For Pa39, no statistically significant difference was observed in the PS and pneumonia models between combined therapy and monotherapy. Moreover,...Continue Reading

References

Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y AsaokaY Nishizuka
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M T QuinnD Steinberg
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·R BalsJ M Wilson
Jun 20, 2003·Lancet·Jean-Louis Vincent
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheol-In KangKang-Won Choe
Dec 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Caius G RaduOwen N Witte
Jan 13, 2004·Nature Medicine·Ji-Jing YanDong-Keun Song
Jun 13, 2009·The Journal of Antimicrobial Chemotherapy·Ali A El Solh, Ahmad Alhajhusain
Mar 9, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Eun-Jeong JooJae-Hoon Song
Nov 17, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y SmaniJ Pachón
Dec 14, 2011·Antimicrobial Agents and Chemotherapy·Carmen PeñaUNKNOWN Spanish Network for Research in Infectious Diseases REIPI
Apr 27, 2013·Pathogens and Disease·Shaan L Gellatly, Robert E W Hancock
Apr 22, 2015·Antimicrobial Agents and Chemotherapy·Younes SmaniJerónimo Pachón
May 7, 2015·Critical Care : the Official Journal of the Critical Care Forum·Scott T MicekVandana Menon
Oct 27, 2015·Pharmacotherapy·Keith S Kaye, Jason M Pogue
Sep 13, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H WrightD L Paterson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.